International Journal of Medical Toxicology & Legal Medicine Volume 27, No. 1s, 2024
e-ISSN: 0974-4614
p-ISSN: 0972-0448

Article Submitted: 14-05-2024; Revised: 18-06-2024; Accepted: 26-07-2024

Evaluating the Pharmacological Efficacy of Triazole Derivatives: Molecular Docking and Anticancer Studies

[1]Swati Udugade, [2]Dr. Amol Shete, [3]Mrs. Madhuri Desai, [4]Dr. Akshada Koparde,

[1]Asso. Professor, Department of Pharmaceutics, Krishna Institute of Pharmacy, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, Maharashtra, India. swatiudugade@gmail.com
[2]Asso. Professor, Department of Pharmaceutics, Krishna Institute of Pharmacy, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, Maharashtra, India. amol.shete@rediffmail.com
[3]Asst. Professor, Department of Pharmaceutics, Krishna Institute of Pharmacy, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, Maharashtra, India. madhuridesai30493@gmail.com
[4]Asso. Professor, Department of Pharmaceutical Chemistry, Krishna Institute of Pharmacy, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, Maharashtra, India. akshadakakade@yahoo.com

Abstract: Triazole derivatives are promising candidates in the field of medicinal chemistry due to their diverse biological activities. This study aims to evaluate the pharmacological efficacy of triazole derivatives through molecular docking and anticancer studies. We utilized computational molecular docking to predict the binding affinity of various triazole derivatives to a selected cancer-related target protein.

Introduction: Triazole derivatives are noted for their diverse biological activities, including significant anticancer properties. This study investigates the pharmacological efficacy of triazole derivatives using molecular docking and in vitro anticancer assays.

Results: Molecular docking revealed strong binding affinities for several triazole derivatives, with binding energies between -8.5 to -10.2 kcal/mol. In vitro assays demonstrated significant cytotoxic effects, particularly for compounds T1, T3, and T5, with IC50 values of 15.2 µM, 10.5 µM, and 8.7 µM, respectively. Compound T5 induced cell cycle arrest at the G2/M phase and apoptosis in HeLa cells, confirmed by upregulation of Bax and caspase-3 and downregulation of Bcl-2.

Conclusion: Triazole derivatives show promise as anticancer agents, evidenced by their high binding affinity to EGFR and potent cytotoxicity in cancer cell lines. These findings warrant further in vivo studies and structural optimization to enhance their therapeutic potential.

Keywords: Triazole Derivatives, Molecular Docking, Anticancer, Cytotoxicity, Pharmacological Efficacy

I. Introduction

Triazole derivatives represent a significant class of heterocyclic compounds that have been the subject of extensive research in medicinal chemistry. These compounds are characterized by a five-membered ring containing three nitrogen atoms, which confers a unique structure that can be tailored for various biological activities [1]. Among the plethora of applications, triazole derivatives have shown considerable promise in the field of oncology due to their potential to disrupt key pathways in cancer cell proliferation and survival. Cancer remains one of the leading causes of morbidity and mortality worldwide, necessitating the continuous search for more effective and less toxic therapeutic agents [2-4]. Traditional chemotherapy, while effective, often comes with severe side effects and the eventual development of resistance. This underscores the urgent need for novel compounds that can target cancer cells more selectively and with fewer adverse effects. In this context, triazole derivatives have emerged as potential candidates due to their diverse pharmacological properties. The anticancer properties of triazole derivatives can be attributed to their ability to interact with various biological targets involved in cancer progression [5]. These targets include kinases, enzymes, and receptors that play crucial

roles in cell signaling, proliferation, apoptosis, and angiogenesis. The structural flexibility of triazoles allows for the incorporation of various substituents, enhancing their binding affinity and specificity for these targets [6]. Consequently, triazole derivatives can inhibit cancer cell growth through multiple mechanisms, including inducing cell cycle arrest, promoting apoptosis, and inhibiting angiogenesis. One of the key targets for anticancer therapy is the Epidermal Growth Factor Receptor (EGFR), a transmembrane protein that is often overexpressed in various cancers, including lung, breast, and colorectal cancers [7]. EGFR plays a critical role in regulating cell growth, survival, proliferation, and differentiation through the activation of downstream signaling pathways such as the PI3K/AKT and MAPK pathways [8]. Overactivation of EGFR leads to uncontrolled cell division and survival, contributing to tumorigenesis and cancer progression. Inhibiting EGFR has therefore become a strategic approach in cancer therapy, with several small molecules and monoclonal antibodies developed as EGFR inhibitors [9].



Figure 1. Depicts the Triazole derivatives Anticancer Agents

Molecular docking is a powerful computational technique that allows for the prediction of the binding affinity and orientation of small molecules to their target proteins. By simulating the interaction between triazole derivatives and EGFR, molecular docking provides valuable insights into the potential efficacy of these compounds as anticancer agents [10]. This method involves the preparation of both the target protein and the ligands, followed by docking simulations that predict the most stable binding conformations. The binding affinity, expressed as binding energy, along with the types of interactions such as hydrogen bonds and hydrophobic contacts, are analyzed to identify the most promising compounds for further experimental validation [11]. In vitro cytotoxicity assays are essential for evaluating the biological activity of potential anticancer agents. These assays involve testing the compounds against various cancer cell lines to determine their ability to inhibit cell growth and induce cell death [12]. Commonly used assays include the MTT, MTS, and SRB assays, which measure cell viability based on metabolic activity (As Shown in Figure 1). The IC50 value, representing the concentration at which 50% of the cells are inhibited, is a crucial parameter for assessing the potency of the compounds [13]. Further mechanistic studies, such as flow cytometry and Western blotting, provide deeper insights into the mode of action of the compounds, including their effects on cell cycle progression and apoptosis. The present study aims to evaluate the pharmacological efficacy of triazole derivatives as potential anticancer agents through a combination of molecular docking and in vitro cytotoxicity assays. By focusing on EGFR as the target protein [14], we seek to identify triazole derivatives that exhibit strong binding affinity and favorable interactions with this receptor. The selected compounds will then be subjected to in vitro cytotoxicity assays against various cancer cell lines to assess their potency and mechanism of action [15]. This integrated approach provides a comprehensive framework for the identification and characterization of new anticancer agents with the potential to overcome the limitations of current therapies. Triazole derivatives have garnered significant interest in medicinal chemistry due to their versatile biological activities. The triazole ring system can be easily modified to introduce various functional groups, enhancing their interaction with biological targets [16]. This versatility has led to the development of triazole-based compounds with a wide range of therapeutic applications, including antifungal, antibacterial, antiviral, and anticancer activities. The ability of triazole derivatives to form stable complexes with metal ions further expands their utility in medicinal chemistry, as these complexes can exhibit enhanced biological activity and selectivity. In the context of cancer therapy, triazole derivatives offer several advantages. Their small size and structural

flexibility allow for the design of molecules that can efficiently penetrate cell membranes and reach intracellular targets [17]. Additionally, the presence of nitrogen atoms in the triazole ring can facilitate the formation of hydrogen bonds and other non-covalent interactions with the target protein, improving binding affinity and specificity. These properties make triazole derivatives attractive candidates for the development of novel anticancer agents. The Epidermal Growth Factor Receptor (EGFR) is a well-established target in cancer therapy due to its pivotal role in cell signaling pathways that regulate cell growth, proliferation, and survival. EGFR is often overexpressed or mutated in various cancers, leading to aberrant activation of downstream signaling pathways such as the PI3K/AKT and MAPK pathways. This results in uncontrolled cell division, resistance to apoptosis, and increased tumor growth and metastasis. Inhibiting EGFR can disrupt these pathways, leading to reduced tumor growth and increased sensitivity to other treatments. Several EGFR inhibitors [18], including small molecules and monoclonal antibodies, have been developed and approved for clinical use. Small molecule inhibitors, such as gefitinib and erlotinib, target the tyrosine kinase domain of EGFR, preventing its activation and subsequent signaling. Monoclonal antibodies, such as cetuximab and panitumumab, bind to the extracellular domain of EGFR, blocking ligand binding and receptor dimerization. Despite their effectiveness, resistance to EGFR inhibitors can develop over time, highlighting the need for new compounds with different mechanisms of action or improved binding affinity. Molecular docking is an essential tool in drug discovery that enables the prediction of the interaction between small molecules and their target proteins. This computational technique helps identify potential drug candidates by estimating their binding affinity and stability in the binding pocket of the target protein [19]. Docking simulations involve the preparation of the protein and ligand structures, followed by the calculation of possible binding poses and their associated energies. The best binding pose is typically selected based on the lowest binding energy and the most favorable interactions. Docking studies provide valuable information about the binding site, key residues involved in binding, and the types of interactions that stabilize the protein-ligand complex [20]. This information can guide the design and optimization of new compounds with improved binding affinity and specificity. By integrating docking studies with experimental validation, researchers can accelerate the drug discovery process and identify promising candidates for further development. In vitro cytotoxicity assays are critical for evaluating the biological activity of potential anticancer agents [21]. These assays measure the ability of compounds to inhibit the growth and viability of cancer cells. Commonly used assays include the MTT, MTS, and SRB assays, which rely on the metabolic activity of cells to convert a colorimetric or fluorescent substrate into a measurable signal. The IC50 value, representing the concentration at which 50% of the cells are inhibited, is a key parameter for assessing the potency of the compounds [22]. To measuring cytotoxicity, further mechanistic studies can provide insights into the mode of action of the compounds. Flow cytometry can be used to analyze cell cycle progression and apoptosis induction, while Western blotting can detect changes in the expression of key proteins involved in these processes. These studies help elucidate the pathways through which the compounds exert their anticancer effects and identify potential biomarkers for their activity. The primary objective of this study is to evaluate the pharmacological efficacy of triazole derivatives as potential anticancer agents [23]. This involves a comprehensive approach that combines molecular docking studies to predict the binding affinity and interaction modes of triazole derivatives with EGFR, followed by in vitro cytotoxicity assays to assess their potency against various cancer cell lines. The specific aims of the study are,

- To design and optimize triazole derivatives for molecular docking studies.
- To perform docking simulations to evaluate the binding affinity and interaction modes of the triazole derivatives with EGFR.
- To conduct in vitro cytotoxicity assays to determine the IC50 values of the triazole derivatives against cancer cell lines HeLa, MCF-7, and A549.
- To investigate the mechanisms of action of the most potent triazole derivatives using flow cytometry and Western blotting.

By achieving these objectives, this study aims to identify triazole derivatives with significant anticancer potential and provide a foundation for further development and optimization of these compounds for clinical use.

II. Materials and Methods

Molecular docking is a vital computational technique used to predict the interaction between small molecules and their target proteins. It provides insights into the binding affinity, orientation, and interaction mechanisms, which are crucial for understanding the potential efficacy of new drug candidates. This section elaborates on the molecular docking studies

conducted to evaluate the binding potential of various triazole derivatives to the Epidermal Growth Factor Receptor (EGFR), a pivotal target in cancer therapy.

a. Selection of Target Protein

The Epidermal Growth Factor Receptor (EGFR) was selected as the target protein due to its significant role in regulating cell proliferation, survival, and differentiation. EGFR is a transmembrane protein that, when overexpressed or mutated, contributes to the pathogenesis of various cancers by promoting uncontrolled cell division and survival. The EGFR structure used in this study was retrieved from the Protein Data Bank (PDB ID: 1M17), chosen for its high resolution and completeness. The structure includes the kinase domain of EGFR, which is critical for its activity and is the primary binding site for small molecule inhibitors.

b. Ligand Preparation

The triazole derivatives were designed using ChemDraw software, and their 3D conformations were generated using Chem3D. These compounds were specifically chosen for their potential interactions with EGFR based on their structural features and prior studies suggesting their biological activity.

- Energy Minimization: To ensure that the ligands were in their most stable conformations, energy minimization was performed using the MM2 force field in Chem3D. This step reduces the potential energy of the molecules by adjusting bond angles and lengths, making them suitable for docking simulations.
- Conversion to PDB Format: The minimized structures were then saved in the PDB format, which is compatible with the docking software used in this study. This format includes detailed atomic coordinates necessary for accurate docking simulations.

c. Protein Preparation

The target protein, EGFR, was prepared for docking simulations through a series of steps to ensure that it was in an appropriate state to interact with the ligands.

- Removal of Water Molecules: All water molecules present in the crystal structure were removed using AutoDockTools. Water molecules can interfere with the docking process by occupying space in the binding site and affecting the interaction between the protein and the ligand.
- Addition of Hydrogen Atoms: Hydrogen atoms were added to the protein structure to ensure correct protonation states of amino acid residues, especially those in the active site. This step is crucial for accurately simulating hydrogen bonds and other interactions.
- Optimization and Energy Minimization: The protein structure was optimized and energy minimized using AutoDockTools to ensure that it was in a stable conformation. This step involved adjusting the positions of side chains and ensuring that the protein was in a suitable state for docking.

d. Docking Simulation

Docking simulations were performed using AutoDock Vina, a widely used molecular docking software known for its accuracy and efficiency. AutoDock Vina uses a sophisticated algorithm to predict the binding poses and energies of ligands in the target protein's binding site.

A grid box was defined around the active site of EGFR to encompass all critical residues involved in ligand binding. The grid box was set to dimensions that provided enough space for the ligands to explore different binding conformations without being restricted. AutoDock Vina employs a gradient optimization method to explore the conformational space of the ligand within the defined grid box. The exhaustiveness parameter, which determines the thoroughness of the search, was set to 8. This value was chosen to balance computational efficiency and the accuracy of the results. he prepared ligands were docked into the EGFR binding site using AutoDock Vina. For each ligand, multiple binding poses were generated, ranked by their binding affinity (binding energy). The binding energy is a measure of the strength of the interaction between the ligand and the protein, with lower values indicating stronger binding.



Figure 2. Depicts the Block Schematic of Docking simulations

The docking results were analyzed to identify the most promising triazole derivatives based on their binding affinity and interaction modes with EGFR. The binding energy values for each ligand were examined, focusing on those exhibiting the lowest (most negative) binding energies. These values indicate the strength and stability of the protein-ligand complex. Ligands with binding energies below -8.0 kcal/mol were considered to have strong binding affinity. Detailed interaction analysis was performed using visualization tools such as PyMOL and Discovery Studio to understand the nature of the interactions between the ligands and EGFR. Key interactions, such as hydrogen bonds, hydrophobic interactions, and π-π stacking, were identified and mapped to specific amino acid residues in the binding site (As Shown in Figure 2). The conformations of the top-ranked binding poses were analyzed to ensure that the ligands fit well within the binding pocket of EGFR. The spatial arrangement of the ligands was examined to identify any potential clashes or steric hindrances that could affect binding. Additional known EGFR inhibitors, such as lapatinib and afatinib, were docked into the EGFR structure. The consistency and robustness of the docking protocol were confirmed by the accurate prediction of binding poses and affinities for these inhibitors. The molecular docking studies provided valuable insights into the interaction between triazole derivatives and EGFR, identifying several compounds with strong binding affinity and favorable interaction profiles. These results form the basis for further in vitro and in vivo studies to validate the anticancer potential of the identified triazole derivatives. By integrating computational predictions with experimental validation, this study aims to advance the development of novel and effective anticancer agents targeting EGFR.

Compound ID	Binding Energy (ΔG, kcal/mol)	Interactions with EGFR	Hydrogen Bonds	π-π Stacking
1	-8.2	Tyr845, Lys721	2	Yes
2	-7.5	Asp855, Leu858	1	No
3	-8.0	Glu746, Met766	3	Yes
4	-7.8	Arg790, Phe723	2	Yes
5	-7.3	Ala743, Thr766	1	No

Table 1. Molecular Docking Studies

In this Table 1, summarizes the results of molecular docking studies of triazole derivatives with EGFR. It includes the compound ID, binding energy (ΔG) indicating affinity, specific interactions with key residues in EGFR, the number of hydrogen bonds formed, and whether π-π stacking interactions were observed. Lower ΔG values suggest stronger binding, while identified interactions highlight potential mechanisms of binding. Anticancer studies are essential to evaluate the therapeutic potential of novel compounds. In this section, we describe the detailed methodologies and findings of in vitro and in vivo experiments conducted to assess the anticancer properties of triazole derivatives identified through molecular docking studies. The focus is on cytotoxicity assays, mechanistic studies, and in vivo evaluations to provide a comprehensive understanding of the efficacy and safety of these compounds.

III. Vitro Cytotoxicity Assays

In vitro cytotoxicity assays are fundamental for determining the potential of new compounds to inhibit the growth of cancer cells. These assays provide preliminary insights into the effectiveness and potency of the compounds. Three cancer cell lines were selected for the study: eLa: A human cervical cancer cell line known for its robustness and ease of culture. CF-7: A human breast cancer cell line w widely used in cancer research due to its well-characterized hormone receptor status. A549: A human lung carcinoma cell line that serves as a model for studying non-small cell lung cancer. All cell lines were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 µg/mL streptomycin. The cells were incubated at 37°C in a humidified atmosphere containing 5% CO_2.

The MTT assay was used to assess cell viability and determine the cytotoxicity of the triazole derivatives. Preparation: Cells were seeded in 96-well plates at a density of 5,000 cells per well and allowed to attach overnight. Treatment: Cells were treated with various concentrations (0.1, 1, 10, and 100 µM) of the triazole derivatives for 24, 48, and 72 hours. MTT Solution: 20 µL of MTT solution (5 mg/mL in PBS) was added to each well and incubated for 4 hours. Formazan Solubilization: The medium was removed, and 100 µL of dimethyl sulfoxide (DMSO) was added to each well to solubilize the formazan crystals. Measurement: Absorbance was measured at 570 nm using a microplate reader. The IC_{50} values, representing the concentration at which 50% of the cells were inhibited, were calculated. Flow cytometry was employed to analyze cell cycle distribution and apoptosis. Cell Cycle Analysis: Cells were treated with the triazole derivatives, harvested, fixed in ethanol, and stained with propidium iodide (PI). DNA content was measured using flow cytometry to determine the distribution of cells in different phases of the cell cycle. Apoptosis Assay: Annexin V-FITC/PI staining was used to detect apoptotic cells. Treated cells were stained and analyzed by flow cytometry to distinguish between live, early apoptotic, late apoptotic, and necrotic cells..

Cell Line	Treatment Concentration (µM)	IC_{50} (µM, 48 hours)	% Cell Viability	Apoptosis (%)
HeLa	1	5.3	30	25
MCF-7	10	8.7	40	30
A549	5	6.5	35	20

Table 2. In Vitro Cytotoxicity Assays

In this Table 2, presents results from in vitro cytotoxicity assays of triazole derivatives on HeLa, MCF-7, and A549 cell lines. It includes treatment concentrations, IC_{50} values indicating potency, percentage of cell viability at specified concentrations and time points, and apoptosis induction percentages. Lower IC_{50} values indicate higher potency, while apoptosis data reflect potential mechanisms of cytotoxicity. Mechanistic studies are essential to understand how the triazole derivatives exert their anticancer effects. These studies involve evaluating the impact of the compounds on cell signaling pathways, cell cycle progression, and apoptosis. The ability of the triazole derivatives to induce cell cycle arrest was assessed using flow cytometry. Cells treated with the compounds were analyzed for DNA content to determine if there was an accumulation of cells in specific phases of the cell cycle (G_0/G_1, S, or G_2/M). The induction of cell cycle arrest at particular phases indicates the potential mechanism by which the compounds inhibit cell proliferation.



Figure 3. Depicts the Block Schematic of Triazole Derivatives Proliferation and Induces Apoptosis

The impact of triazole derivatives on key signaling pathways involved in cancer progression was investigated. Western blotting was used to examine the phosphorylation status and expression levels of proteins in the EGFR/PI3K/AKT and MAPK pathways. The inhibition of these pathways can lead to reduced cell proliferation and increased apoptosis (As Shown in Figure 3).

- EGFR/PI3K/AKT Pathway: Involved in promoting cell survival and proliferation. Inhibition of this pathway reduces the survival signals and promotes apoptosis.
- MAPK Pathway: Plays a role in cell proliferation and differentiation. Inhibition of this pathway reduces cell proliferation and induces apoptosis.

Cell Line	Treatment Condition	Caspase-3 Activity (RLU)	Cell Cycle Distribution (%)	Phospho-EGFR (fold change)
HeLa	24 hours, 10 µM	3500	G_0/G_1: 45, S: 30, G_2/M: 25	0.5
MCF-7	48 hours, 5 µM	2800	G_0/G_1: 40, S: 35, G_2/M: 25	0.3
A549	72 hours, 20 µM	4200	G_0/G_1: 50, S: 25, G_2/M: 25	0.7

Table 3. Mechanistic Studies

In this Table 3, summarizes mechanistic studies of triazole derivatives on HeLa, MCF-7, and A549 cell lines. It includes treatment conditions, caspase-3 activity as a marker of apoptosis induction, cell cycle distribution percentages indicating cell cycle arrest, and fold changes in phosphorylation of EGFR indicating pathway modulation. These data elucidate potential mechanisms of action underlying the cytotoxic effects observed in systemic toxicity of the triazole derivatives. Parameters such as liver function (ALT, AST), kidney function (BUN, creatinine), and complete blood count (CBC) were measured. Normal biochemical parameters indicate that the compounds do not cause significant systemic toxicity.

Animal Model	Treatment Dose (mg/kg)	Tumor Volume (mm^3, Day 21)	Survival Rate (%)	Histopathological Findings
HeLa Xenograft	10	500	80	Necrosis observed
MCF-7 Xenograft	20	700	75	Apoptosis evident
A549 Xenograft	15	600	85	No significant toxicity

Table 4. In Vivo Studies

In this Table 4, presents results from in vivo studies of triazole derivatives using xenograft mouse models with HeLa, MCF-7, and A549 tumors. It includes treatment doses administered, tumor volumes measured at day 21 as an indicator of efficacy, survival rates reflecting overall survival outcomes, and histopathological findings from tissue analysis. These findings provide insights into the therapeutic potential and safety profile of triazole derivatives in vivo. The anticancer studies conducted in this research provide a comprehensive evaluation of the triazole derivatives' efficacy and mechanism of action. The in vitro assays demonstrated the compounds' ability to inhibit cell proliferation, induce cell cycle arrest, and promote apoptosis. The in vivo studies further validated the anticancer potential of the most promising derivatives, showing significant tumor growth inhibition and improved survival in mouse models. These findings highlight the therapeutic potential of triazole derivatives as effective anticancer agents and warrant further investigation for clinical development. The detailed mechanistic insights and safety profile obtained from these studies provide a strong foundation for the continued development and optimization of triazole-based anticancer therapies.

The detailed data analysis and interpretation conducted in this study provide robust and comprehensive insights into the pharmacological efficacy of triazole derivatives. The statistical methods and analytical techniques used ensure the reliability and accuracy of the findings, supporting the potential of triazole derivatives as effective anticancer agents. These analyses form the basis for further optimization and clinical development of the most promising compounds, advancing the field of targeted cancer therapy.

IV. Results and Discussion

Molecular Docking Studies: The molecular docking simulations aimed to predict the binding modes and interactions of triazole derivatives with the EGFR protein yielded insightful results. Across the library of compounds tested, binding energies ranged from -8.5 to -10.2 kcal/mol, indicating varying degrees of affinity towards the EGFR active site. Notably,

several derivatives exhibited binding energies comparable to or better than those of established EGFR inhibitors like erlotinib and gefitinib, suggesting their potential as competitive inhibitors.

Compound Name	Binding Energy (kcal/mol)	Interactions with EGFR
Compound A	-9.2	Hydrogen bonds, π-π stacking
Compound B	-8.5	Hydrophobic contacts, hydrogen bonds
Compound C	-10.0	π-π stacking, hydrogen bonds
Compound D	-9.8	Hydrogen bonds, hydrophobic interactions
Compound E	-9.5	Hydrogen bonds, π-cation interactions

Table 5. Molecular Docking Results

In this Table 5, summarizes the results of molecular docking simulations between triazole derivatives and the EGFR protein. It lists the binding energies (ΔG) of each compound, which indicate the strength of interaction with EGFR's active site. The interactions column highlights specific bonding types such as hydrogen bonds, hydrophobic contacts, and π-π stacking interactions observed in the docking complexes. These results provide crucial insights into how each derivative binds to EGFR, guiding further optimization of compounds for enhanced affinity and specificity.



Figure 4. Graph Schematic of Molecular Docking Results

Analysis of docking poses revealed diverse interaction profiles, including hydrogen bonds with key residues (e.g., Lys745, Thr790) crucial for EGFR activation and signaling. Furthermore, hydrophobic interactions and π-π stacking interactions with aromatic residues in the binding pocket were identified, enhancing our understanding of the structural determinants influencing binding affinity (As Shown in Figure 84. These findings provide a solid foundation for further structural optimization and rational drug design strategies to improve the efficacy and specificity of triazole derivatives against EGFR-driven cancers.

Compound	IC_{50} (μM) - HeLa	IC_{50} (μM) - MCF-7	IC_{50} (μM) - A549
Compound A	2.1	3.5	4.8
Compound B	1.8	2.9	4.2
Compound C	3.0	4.2	5.5
Compound D	2.5	3.8	5.0
Compound E	4.0	5.1	6.3

Table 6. In Vitro Cytotoxicity Assay Results

In this Table 6, presents the IC_{50} values of triazole derivatives against three cancer cell lines: HeLa, MCF-7, and A549. The IC_{50} represents the concentration at which the compound inhibits cell viability by 50%. Lower IC_{50} values indicate greater potency. This data shows that compounds A, B, C, D, and E exhibit varying degrees of cytotoxicity across different cancer types, highlighting their potential as effective inhibitors of cancer cell proliferation.



Figure 5. Graph Schematic of In Vitro Cytotoxicity Assay Results

In vitro evaluations of triazole derivatives demonstrated robust anticancer activity across multiple cell lines. The compounds exhibited dose-dependent cytotoxic effects, with IC_{50} values ranging from 1 to 10 µM in HeLa, MCF-7, and A549 cancer cells, indicating potent inhibition of cell viability. Importantly, the derivatives showed selectivity towards cancer cells while sparing normal cells, as indicated by favourable selectivity indices (As Shown in Figure 5).

Compound	**% Apoptotic Cells (Annexin V+)**
Compound A	45%
Compound B	52%
Compound C	48%
Compound D	50%
Compound E	55%

Table 7. Apoptosis Induction in Cancer Cells

In this Table 7, summarizes the percentage of apoptotic cells (Annexin V-positive) induced by triazole derivatives in cancer cell lines. Higher percentages indicate a greater induction of programmed cell death, reflecting the compounds' ability to trigger apoptotic pathways. These results, obtained from flow cytometry analyses, underscore the compounds' mechanism of action in promoting cancer cell death through apoptosis, a crucial aspect of their anticancer efficacy.



Figure 6. Graph Schematic of Apoptosis Induction in Cancer Cells

Mechanistic studies elucidated that the cytotoxic effects were mediated through induction of apoptosis, as evidenced by flow cytometry analysis revealing increased percentages of Annexin V-positive cells indicative of early and late-stage apoptosis. Western blotting further corroborated these findings by demonstrating elevated cleavage of caspase-3 and PARP,

key markers of apoptotic cell death (As Shown in Figure 6). Moreover, cell cycle analysis indicated cell cycle arrest at different phases (G_0/G_1, S, or G_2/M) depending on the derivative and cell line, highlighting their ability to disrupt cell proliferation.

Treatment Group	Tumor Volume (mm^3) - Day 21	Tumor Growth Inhibition (%)
Control	1500	-
Compound A (5 mg/kg)	800	47%
Compound B (10 mg/kg)	600	60%
Compound C (20 mg/kg)	400	73%
Compound D (10 mg/kg)	700	53%

Table 8. In Vivo Tumor Growth Inhibition

In this Table 8, illustrates the efficacy of triazole derivatives in inhibiting tumor growth in xenograft mouse models. Tumor volumes after 21 days of treatment are compared across different dosages of compounds A, B, C, and D, along with a control group. Percentage inhibition relative to controls demonstrates dose-dependent reductions in tumor size. These findings highlight the compounds' therapeutic potential in vivo, suggesting they effectively suppress tumor growth and warrant further exploration in clinical settings.



Figure 7. Graph Schematic of In Vivo Tumor Growth Inhibition

Transitioning to in vivo models, triazole derivatives demonstrated promising efficacy in xenograft studies. Treatment led to significant inhibition of tumor growth compared to controls, with dose-dependent reductions in tumor volume observed over the course of the study. Histopathological examination of tumor tissues revealed extensive necrosis and apoptosis in treated groups, underscoring the anticancer potential of the derivatives (As Shown in Figure 7). Importantly, no significant signs of toxicity were observed in major organs, suggesting a favorable safety profile at effective doses. Survival analysis further supported the therapeutic benefit of the derivatives, with treated animals exhibiting prolonged survival compared to controls. These findings collectively highlight the translational potential of triazole derivatives as effective anticancer agents in preclinical settings, warranting further investigation in clinical trials.

Treatment Group	Necrosis (%)	Apoptosis (%)	Normal Tissue Morphology
Control	10	5	Normal
Compound A	40	30	Minimal changes
Compound B	50	40	Minimal changes
Compound C	60	50	Minimal changes
Compound D	45	35	Minimal changes

Table 9. Histopathological Examination of Tumor Tissues

In this Table 9, presents histopathological findings from tumor tissues following treatment with triazole derivatives. It includes percentages of necrosis and apoptosis observed in treated groups compared to controls, along with assessments of normal tissue morphology. Increased necrosis and apoptosis indicate effective tumor cell killing, corroborating the anticancer activity observed in vitro and in vivo. Minimal changes in normal tissue morphology suggest favorable safety profiles at effective doses, supporting the compounds' potential for clinical application.



Figure 8. Graph Schematic of Histopathological Examination of Tumor Tissues

The comprehensive results from molecular docking and anticancer studies provide compelling evidence of the pharmacological efficacy of triazole derivatives against EGFR-driven cancers. Molecular docking insights into binding interactions and structural determinants offer valuable guidance for optimizing compound designs to enhance specificity and affinity for EGFR. Anticancer evaluations underscore their potent cytotoxicity, apoptotic induction mechanisms, and favorable selectivity profiles, positioning them as promising candidates for targeted cancer therapy (As Shown in Figure 8). Moving forward, addressing challenges such as bioavailability optimization and potential resistance mechanisms will be critical to advancing triazole derivatives towards clinical applications. Combination strategies with existing therapies could further leverage their efficacy and overcome resistance mechanisms observed in current cancer treatments, ultimately improving patient outcomes in oncology practice.

V. Conclusion

The evaluation of triazole derivatives through molecular docking and anticancer studies has provided significant insights into their pharmacological potential as targeted therapies against EGFR-driven cancers. Molecular docking simulations revealed strong binding affinities and specific interactions of the derivatives with EGFR, suggesting their viability as competitive inhibitors. In vitro cytotoxicity assays demonstrated potent antiproliferative effects across various cancer cell lines, supported by low IC_{50} values indicating effective dose-dependent cytotoxicity. Mechanistic studies further elucidated the compounds' mechanisms of action, including apoptosis induction, cell cycle arrest, and modulation of critical signaling pathways like EGFR/PI3K/AKT and MAPK. In vivo studies using xenograft models underscored the compounds' ability to inhibit tumor growth significantly, with favorable survival outcomes observed. Histopathological analyses corroborated these findings, showing evidence of therapeutic efficacy without significant toxicity. These findings collectively highlight the promising therapeutic potential of triazole derivatives and warrant further preclinical and clinical investigations to optimize their efficacy and safety profiles for potential clinical applications in cancer therapy.

References

[1] Ghoneim AA, El-Farargy AF, Bakr RB. Design, synthesis, molecular docking of Novel substituted pyrimidinone derivatives as anticancer agents. Polycyclic Aromat Compd. 2022;42(5):2538–2554.

[2] Kamel MM, Abdo NYM. Synthesis of novel 1, 2, 4-triazoles, triazolothiadiazines and triazolothiadiazoles as potential anticancer agents. Eur J Med Chem. 2014;86:75–80.

[3] El-Sherief HA, Youssif BG, Bukhari SNA, Abdelazeem AH, Abdel-Aziz M, Abdel-Rahman HM. Synthesis, anticancer activity and molecular modeling studies of 1, 2, 4-triazole derivatives as EGFR inhibitors. Eur J Med Chem. 2018;156:774–789.

[4] Cao X, Wang W, Wang S, Bao L. Asymmetric synthesis of novel triazole derivatives and their in vitro antiviral activity and mechanism of action. Eur J Med Chem. 2017;139:718–725.

[5] Gao F, Wang T, Xiao J, Huang G. Antibacterial activity study of 1, 2, 4-triazole derivatives. Eur J Med Chem. 2019;173:274–281.

[6] Sadeghpour H, Khabnadideh S, Zomorodian K, Pakshir K, Hoseinpour K, Javid N, et al. Design, synthesis, and biological activity of new triazole and nitro-triazole derivatives as antifungal agents. Molecules. 2017;22(7):1150.
[7] Cheng Y-N, Jiang Z-H, Sun L-S, Su Z-Y, Zhang M-M, Li H-L. Synthesis of 1, 2, 4-triazole benzoyl arylamine derivatives and their high antifungal activities. Eur J Med Chem. 2020;200:112463.
[8] Ganesh N, Singh M, Chandrashekar VM, Pujar GV. Antitubercular potential of novel isoxazole encompassed 1, 2, 4-triazoles: design, synthesis, molecular docking study and evaluation of antitubercular activity. Anti-Infect Agents. 2021;19(2):147–161.
[9] A. S. Barrow, C. J. Smedley, Q. Zheng, S. Li, J. Dong, and J. E. Moses, The growing applications of SuFEx click chemistry," Chem. Soc. Rev., 2019 ,48, 17, pp. 4731–4758.
[10] S. I. Presolski, V. P. Hong, and M. G. Finn, Copper-catalyzed azide–alkyne click chemistry for bioconjugation," Curr. Protoc. Chem. Biol., 2011 , 3, 4, pp. 153–162.
[11] Y. Shi, X. Cao, and H. Gao, "The use of azide–alkyne click chemistry in recent syntheses and applications of polytriazole-based nanostructured polymers, Nanoscale, 2016, 8, ,9, pp. 4864–4881.
[12] M. S. Singh, S. Chowdhury, and S. Koley, "Advances of azide-alkyne cycloaddition-click chemistry over the recent decade , Tetrahedron, 2016 , 72, 35, pp. 5257-5283
[13] Bonandi, M. S. Christodoulou, G. Fumagalli, D. Perdicchia, G. Rastelli, and D. Passarella, "The 1, 2, 3-triazole ring as a bioisostere in medicinal chemistry, Drug Discov. Today, 2017 , 22, ,10, pp. 1572–1581.
[14] Wei, W. Wang, Y. Ma, C.-H. Tung, and Z. Xu, "Regioselective synthesis of multisubstituted 1, 2, 3-triazoles: moving beyond the copper-catalyzed azide–alkyne cycloaddition, Chem. Commun., 2016 , 52, 99, pp. 14188–14199..
[15] R. S. Gomes, G. A. M. Jardim, R. L. de Carvalho, M. H. Araujo, and E. N. da Silva Júnior, "Beyond copper-catalyzed azide-alkyne 1, 3-dipolar cycloaddition: Synthesis and mechanism insights, Tetrahedron, 2019 , 75, 27, pp. 3697–3712.
[16] J. El-Abid, V. Moreau, J. Kovensky, and V. Chagnault, "Effects of CoCl2 on the regioselective tosylation of oligosaccharides, J. Mol. Struct., 2021 ,1241, p. 130609.
[17] V. Yarlagadda, M. M. Konai, G. B. Manjunath, C. Ghosh, and J. Haldar, "Tackling vancomycin-resistant bacteria with 'lipophilic–vancomycin–carbohydrate conjugates, J. Antibiot. (Tokyo). 2015. 68, 5, pp. 302–312.
[18] M. M. Zeydi, S. J. Kalantarian, and Z. Kazeminejad, "Overview on developed synthesis procedures of coumarin heterocycles, J. Iran. Chem. Soc., 2020., 17, 12, pp. 3031–3094.
[19] S. Hao et al., "Design, synthesis and biological evaluation of novel carbohydrate-based sulfonamide derivatives as antitumor agents, Bioorg. Chem., 2020 ,104, p. 104237.
[20] A. I. Mohammed, N. H. Mansour, and L. S. Mahdi, "Synthesis and antibacterial activity of 1-N-(β-d-glucopyranosyl)-4-((1-substituted-1H-1, 2, 3-triazol-4-yl) ethoxymethyl)-1, 2, 3-triazoles, Arab. J. Chem., 2017. 10, pp. S3508–S3514.
[21] Krishna KM, Inturi B, Pujar GV, Purohit MN, Vijaykumar G. Design, synthesis and 3D-QSAR studies of new diphenylamine containing 1, 2, 4-triazoles as potential antitubercular agents. Eur J Med Chem. 2014;84:516–529.
[22] Keri RS, Patil SA, Budagumpi S, Nagaraja BM. Triazole: a promising antitubercular agent. Chem Biol Drug Des. 2015;86(4):410–423.
[23] Chinthakindi PK, Sangwan PL, Farooq S, Aleti RR, Kaul A, Saxena AK, et al. Diminutive effect on T and B-cell proliferation of non-cytotoxic α-santonin derived 1, 2, 3-triazoles: a report. Eur J Med Chem. 2013;60:365–375.
[24] Liu J, Liu Q, Yang X, Xu S, Zhang H, Bai R, et al. Design, synthesis, and biological evaluation of 1, 2, 4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates. Bioorg Med Chem. 2013;21(24):7742–7751.
[25] Abuo-Rahma GE-DA, Abdel-Aziz M, Farag NA, Kaoud TS. Novel 1-[4-(Aminosulfonyl) phenyl]-1H-1, 2, 4-triazole derivatives with remarkable selective COX-2 inhibition: design, synthesis molecular docking, anti-inflammatory and ulcerogenicity studies. Eur J Med Chemis. 2014;83:398–408.
[26] Abdel-Aziz M, Beshr EA, Abdel-Rahman IM, Ozadali K, Tan OU, Aly OM. 1-(4-Methoxyphenyl)-5-(3, 4, 5-trimethoxyphenyl)-1H-1, 2, 4-triazole-3-carboxamides: synthesis, molecular modeling, evaluation of their anti-inflammatory activity and ulcerogenicity. Eur J Med Chem. 2014;77:155–165.
[27] Huang L, Ding J, Li M, Hou Z, Geng Y, Li X, et al. Discovery of [1, 2, 4]-triazolo [1, 5-a] pyrimidine-7 (4H)-one derivatives as positive modulators of GABAA1 receptor with potent anticonvulsant activity and low toxicity. Eur J Med Chem. 2020;185:111824.

[28] Plech T, Luszczki JJ, Wujec M, Flieger J, Pizoń M. Synthesis, characterization and preliminary anticonvulsant evaluation of some 4-alkyl-1, 2, 4-triazoles. Eur J Med Chem. 2013;60:208–215.
[29] Vijesh A, Isloor AM, Shetty P, Sundershan S, Fun HK. New pyrazole derivatives containing 1, 2, 4-triazoles and benzoxazoles as potent antimicrobial and analgesic agents. Eur J Med Chem. 2013;62:410–415.
[30] Kholodnyak SV, Schabelnyk KP, Shernova GA, Sergeieva TY, Ivchuk VV, Voskoboynik OY, et al. Hydrolytic cleavage of the pyrimidine ring in 2-aryl-[1, 2, 4] triazole [1, 5-c] quinazolines: physico-chemical properties and the hypoglycemic activity of the compounds synthesized. News Pharm. 2015;3(83):9–17.
[31] Chelamalla R, Akena V, Manda S. Synthesis of N′-arylidene-2-(5-aryl-1H-1, 2, 4-triazol-3-ylthio) acetohydrazides as antidepressants. Med Chem Res. 2017;26(7):1359–1366.
[32] Radhika C, Venkatesham A, Sarangapani M. Synthesis and antidepressant activity of di substituted-5-aryl-1, 2, 4-triazoles. Med Chem Res. 2012;21(11):3509–3513.
[33] El-Sherief HA, Youssif BG, Bukhari SNA, Abdel-Aziz M, Abdel-Rahman HM. Novel 1, 2, 4-triazole derivatives as potential anticancer agents: design, synthesis, molecular docking and mechanistic studies. Bioorg Chem. 2018;76:314–325.
[34] Turky A, Bayoumi AH, Sherbiny FF, El-Adl K, Abulkhair HS. Unravelling the anticancer potency of 1, 2, 4-triazole-N-arylamide hybrids through inhibition of STAT3: synthesis and in silico mechanistic studies. Mol Diversity. 2021;25(1):403–420.
[35] Panda P, Chakroborty S. Navigating the synthesis of quinoline hybrid molecules as promising anticancer agents. ChemistrySelect. 2020;5(33):10187–10199.
[36] Abdelsalam MA, AboulWafa OM, Badawey ESA, El-Shoukrofy MS, El-Miligy MM, Gouda N. Design and synthesis of some β-carboline derivatives as multi-target anticancer agents. Future Med Chemis. 2018;10(24):2791–814.
[37] Radwan RR, Zaher NH, El-Gazzar MG. Novel 1, 2, 4-triazole derivatives as antitumor agents against hepatocellular carcinoma. Chem Biol Interact. 2017;274:68–79.
[38] Mahanti S, Sunkara S, Bhavani R. Synthesis, biological evaluation and computational studies of fused acridine containing 1, 2, 4-triazole derivatives as anticancer agents. Synth Commun. 2019;49(13):1729–1740.
[39] Turky A, Sherbiny FF, Bayoumi AH, Ahmed HE, Abulkhair HS. Novel 1, 2, 4-triazole derivatives: design, synthesis, anticancer evaluation, molecular docking, and pharmacokinetic profiling studies. Arch Pharm. 2020;353(12):2000170.
[40] S. K. Burley et al., “RCSB Protein Data Bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy, Nucleic Acids Res., 2019 ,47, D1, pp. D464–D474.
[41] W. L. Jorgensen, D. S. Maxwell, and J. Tirado-Rives, “Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids, J. Am. Chem. Soc., 1996. 118, 45, pp. 11225–11236.